Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The US Attorney's Office for the Northern District of California said earlier this week that cancer testing company Guardant Health has agreed to settle allegations that it knowingly violated the False Claims Act and regulations of the Defense Health Agency.

Agilent Technologies Inc. (NYSE: A) today announced the release of its new ProteoAnalyzer system, in addition to existing product updates at the Singapore Cell and Gene Therapy Pan Asia Summit (SCGT).

GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024.

Lawmakers have told the Food and Drug Administration to suspend efforts to implement its final rule on laboratory developed tests (LDTs).

Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx).

Celebrating the 10th anniversary of Advanced Science and the 5th anniversary of VIEW, the Advanced Science/VIEW Symposium: Advances in Biomedical Research And 2nd International Symposium on Materiobiology took place in Shanghai on 13-14 July 2024.

Diasorin (FTSE MIB: DIA) today announced that the Food and Drug Administration (FDA) has granted de-novo authorization for the Simplexa® C. auris Direct kit to test patients suspected of Candida auris colonization and aid in preventing potential spread in healthcare settings. This real-time polymerase chain reaction (RT-PCR) assay is used for the direct in vitro qualitative detection of C.auris DNA from a swab of axilla/groin from patients suspected of C. auris colonization, and detects the six C.auris clades that are circulating globally.

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.

In 2019, the State Council successively promulgated three policy documents closely related to the biochemical analysis instruments and reagents, which laid an important policy foundation for the development of biochemical analysis instruments and reagents.

Oncocyte Corporation, a company specializing in in vitro and in vivo diagnostic substances, has regained compliance with Nasdaq's listing rules regarding board and audit committee composition. The notice of compliance was received by the company on Monday, following a period of noncompliance caused by the passing of director Alfred D. Kingsley on April 25, 2024.

Alzpath said Monday that it has signed a licensing agreement with Beckman Coulter Diagnostics for use of the Alzpath phosphorylated-tau 217 antibody in a blood-based test for Alzheimer's disease.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.